Shannon N. Westin, MD, MPH, Discussed the Wee1 Inhibitor Adavosertib for PARPi-Resistant Ovarian Cancer

Video

CancerNetwork® sat down with Shannon N. Westin, MD, MPH, at the 2021 ASCO Annual Meeting to talk about the use of adavosertib in PARP inhibitor–resistant ovarian cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Shannon N. Westin, MD, MPH, of the University of Texas MD Anderson Cancer Center, about efficacy with the Wee1 inhibitor adavosertib observed in the phase 2 EFFORT trial (NCT03579316). In a patient population with a median of 4 prior lines of therapy, the agent showed a 23% overall response rate. Toxicity led to dose interruptions in most patients, but grade 3/4 adverse effects were considered to be manageable.

Here, Westin discusses how these data may be of use to the multidisciplinary team.

Transcript:

Similar to what we’ve seen with other combination strategies, it really is important to engage the patient, your pharmacist, and your nursing staff to make sure that everybody’s aware of the potential [adverse] effects and set expectations to really make sure patients know we may start on 1 dose, but there may be a need to hold and to reduce as needed to make this tolerable for you. I think that would be the major thing.

Now as far as where this is going. Scientifically, this is very exciting that clinically we’re seeing the benefit we need, but it’s not quite ready for primetime. We need to do a little bit more study before it’s going to be [in] the hands of clinicians out in practice.

References

Westin SN, Coleman RL, Fellman BM, et al. EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. J Clin Oncol. 2021;39(suppl 15):5505. doi:10.1200/JCO.2021.39.15_suppl.5505

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Related Content